Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)
暂无分享,去创建一个
K. Gelmon | A. Tolcher | M. Carducci | L. Siu | A. Kalita | C. Maroun | Zuomei Li | J. Besterman | C. Bonfils | G. Reid